AIDS InfoNet Logo
This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

The Henry J. Kaiser Family Foundation
Site of the Week
November 2003

The Health Leader Award 2006
The Health Leader Award 2006

The HOPE Reward Medical Award Featured Site Award

IBS Tales Hope Award Editor's Choice Award

Listed in Listed in Treasures of the Internet

AIDS InfoNet Logo.  The AIDS InfoNet - Reliable, Up-to-Date AIDS Treatment Information
International Association of Providers of AIDS Care
Reviewed February 24, 2014

Fact Sheet 411

Zidovudine (Retrovir, AZT)




Zidovudine (Retrovir) is a drug used for antiretroviral therapy (ART). It was first manufactured by GlaxoSmithKline. It is manufactured by ViiV Healthcare. The patent on zidovudine expired in 2005 and several generic versions have been approved.  Several are available under PEPFAR (see fact sheet 925).  Zidovudine is also known as azido-deoxythymidine, AZT or ZDV.

Zidovudine was the first drug approved for the treatment of HIV. It is a nucleoside analog reverse transcriptase inhibitor, or nuke. These drugs block the reverse transcriptase enzyme. This enzyme changes HIV’s genetic material (RNA) into the form of DNA. This has to occur before HIV’s genetic code gets inserted into an infected cell’s own genetic codes.



Zidovudine was approved in 1987 as an antiretroviral (ARV) drug for people with HIV infection. Recommended dosages are available for children over 6 weeks old.  It may also be used to prevent transmission of HIV from a pregnant women to her newborn baby (see fact sheet 611.)

There are no absolute rules about when to start ART. You and your health care provider should consider your CD4 cell count, your viral load, any symptoms you are having, and your attitude about taking HIV medications. Fact Sheet 404 has more information about guidelines for the use of ART.

If you take zidovudine with other ARV drugs, you can reduce your viral load to extremely low levels, and increase your CD4 cell counts. This should mean staying healthier longer.

Because zidovudine was the first ARV approved, it has been studied more than any other drug. Most new drugs have been tested by comparing them to zidovudine.

“Early treatment” with zidovudine was tested in people with no symptoms of HIV disease. The study showed no benefit to taking zidovudine. But zidovudine is used as part of combination therapy for people who are exposed to HIV through a workplace accident (needle stick or splash).

Zidovudine greatly reduces transmission of HIV from the mother to her child. It has been given to HIV-positive pregnant women from the 4th month of pregnancy until their baby is born, and to the newborn baby for 6 weeks. However, due to its side effects, it is not recommended when the mother’s viral load is below 400.



Many new copies of HIV are mutations. They are slightly different from the original virus. Some mutations can keep multiplying even when you are taking an ARV drug. When this happens, the drug will stop working. This is called “developing resistance” to the drug. See Fact Sheet 126 for more information on resistance.

Sometimes, if your virus develops resistance to one drug, it will also have resistance to other ARVs. This is called “cross-resistance”.

Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.



The recommended dose of zidovudine for adults is 500mg to 600mg daily. Zidovudine comes in 100mg capsules and 300mg tablets. It is also available in liquid form. In 2011 the FDA approved a 100 mg tablet that can be dissolved in water. In 2009 the FDA approved new dosing guidelines for children at least 4 weeks old. The dose is based on weight. The new guidelines allow for three times or twice daily dosing.

Zidovudine is also available in Combivir and Trizivir. Combivir contains zidovudine and lamivudine. Trizivir contains zidovudine, lamivudine, and abacavir. For more information, see Fact Sheet 417 on Combivir or Fact Sheet 418 on Trizivir.



When you start ART you may have temporary side effects such as headaches, high blood pressure, or a general sense of feeling ill. These side effects usually get better or disappear over time. Some patients taking zidovudine continue to have nausea, vomiting, headaches and fatigue.

The most serious side effects of zidovudine are anemia, neutropenia and myopathy. These side effects are not common.

Anemia is a shortage of red blood cells caused by damage to bone marrow. It is most common in newborn infants taking zidovudine but disappears after they stop taking the drug.  If you get anemia, your doctor might reduce your dose or switch zidovudine for another ARV. If the anemia is severe and you have to keep taking zidovudine, you may need a blood transfusion, or you might take the drug erythropoietin. For more information on anemia, see Fact Sheet 552.

Myopathy is muscle pain and weakness. There is no specific treatment for myopathy.

Neutropenia is an abnormally low number of neutrophils, the most common type of white blood cell. Neutropenia increases the risk of bacterial and fungal infections.

Changes in skin and nail color (darkening of skin and nails) can also occur.  This is more common in people with darker skin.



 Zidovudine can interact with other drugs or supplements you are taking. These interactions can change the amount of each drug in your bloodstream and cause an under- or overdose. New interactions are constantly being identified. Make sure that your health care provider knows about ALL drugs and supplements you are taking. . Zidovudine should not be combined with stavudine (d4T, Zerit).

Zidovudine’s side effects may be worse if taken with several other drugs. .

Methadone may increase blood levels of zidovudine. If you take zidovudine and methadone, watch for zidovudine side effects.



Back to Fact Sheet Categories

International Association of Providers of AIDS Care


The AIDS InfoNet is a project of the International Association of Providers of AIDS Care.


United States National Library of Medicine

Partially funded by the National Library of Medicine

Search Our Site
Newest Fact Sheets
Print This Fact Sheet
You can print this fact sheet on a single page in Microsoft Word (.doc) format or Adobe Acrobat (.pdf) format. Click on the links below to open the document in your browser and then print it.
 Adobe Acrobat PDF
 Microsoft Word

You can print directly from your browser using the link below. The printout will probably go onto a second page.
 Print Version (Web)

Monthly E-mail Updates

The InfoNet updates its Fact Sheets frequently. A listing of each month's changes is posted to several e-mail lists.

If you would like to receive this monthly update by personal e-mail, please click on the SUBMIT button.